Off-the-Shelf CAR-T cells take on tough blood cancers

NCT ID NCT06662227

Terminated Disease control Sponsor: Wondercel Biotech (ShenZhen) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along with short-term immunosuppression to prevent rejection. The main goals are to find a safe dose and check for any early signs that the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: universal CD19-targeted CAR-T cells (UWD-19) plus mycophenolate immunosuppression
What this could lead to: If successful, this could point toward a readily available 'off-the-shelf' cell therapy for hard-to-treat B-cell cancers, reducing the need for personalized manufacturing.
What could go wrong: This is a very early (Phase 1), small (30 people), suspended trial. CAR-T therapy carries risks of severe side effects like cytokine release syndrome and neurological problems. The universal approach may also be rejected by the immune system or lose effectiveness over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE B LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell neoplasm Leukemia, B-Cell precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA B-CELL LEUKEMIA B-CELL MALIGNANCY

Contacts and locations

Locations

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.